Linked from

The 36 pages that link to Overdiagnosis, each with the reason it gives.

• Evidence-based medicineRelated: Evidence-based evaluation of screening weighs potential benefits against harms from detecting inconsequential disease.

• Medical imagingRelated: Screening images can detect abnormalities whose treatment may offer no benefit.

• Medical diagnosisRelated: Finding clinically harmless disease can lead to needless treatment and distress.

• MedicalizationRelated: It identifies one potential consequence when medical categories expand into low-risk populations.

• Psychiatric diagnosisRelated: Expanding criteria can classify ordinary variation or transient distress as disorder.

• BiomarkerRelated: Sensitive biomarker screening can detect abnormalities whose treatment offers no benefit and may cause harm.

• DSM-5Related: Critics argue that expanded or lowered thresholds can classify ordinary distress as disorder.

• False positiveRelated: False-positive screening can lead to diagnoses and treatment of harmless findings.

• Diagnostic testRelated: More sensitive testing can find abnormalities that do not benefit from treatment.

• Clinical diagnosisRelated: It shows how a technically correct label can still lead to unnecessary care.

• Prostate cancerRelated: PSA screening can find indolent prostate tumors that would not otherwise matter clinically.

• Sensitivity and specificityRelated: Sensitive screening can find abnormalities whose detection does not improve health.

• Cancer stagingRelated: Earlier detection can identify indolent cancers whose assigned stage may prompt questions about treatment benefit.

• Variant of uncertain significanceRelated: Misreading an uncertain variant as disease-causing can prompt unnecessary diagnosis and intervention.

• Secondary preventionRelated: Some screening programs can cause treatment and anxiety without preventing meaningful harm.

• Preventive medicineRelated: Its frequency complicates decisions about whether and how often to screen.

• Watchful waitingRelated: Observation can limit unnecessary treatment after detecting indolent disease.

• DiseaseRelated: It shows how detecting an abnormality can classify someone as diseased without improving outcomes.

• Developmental screeningRelated: Screening can expand follow-up and labeling, so benefits must be weighed against potential harms.

• Breast cancerRelated: Some screen-detected breast cancers may never become clinically consequential.

• Liquid biopsyRelated: Sensitive screening may find indolent cancers that would not otherwise affect health.

• OncologyRelated: It is a central concern when screening finds slow-growing cancers unlikely to become harmful.

• Cancer surveillanceRelated: Surveillance can find slow-growing tumors whose detection may not improve health outcomes.

• Cancer researchRelated: Screening research must measure this harm alongside earlier detection.

• Genetic screeningRelated: Screening can identify variants or conditions whose detection offers no health benefit.

• Prostate-specific antigenRelated: PSA screening can find slow-growing cancers that would never have harmed a person.

• Preventive healthcareRelated: Screening can find disease that would not otherwise affect health, creating potential harm.

• Medical testRelated: More sensitive testing can find abnormalities whose detection does not improve health.

• Pap testRelated: Screening may identify low-grade changes that regress without treatment.

• Li–Fraumeni syndromeRelated: Intensive surveillance can find abnormalities whose clinical importance is uncertain.

• TherapeuticsRelated: It can expose people to treatment harms without corresponding benefit.

• Medical physics and public healthRelated: Screening can increase diagnosis without reducing illness or death proportionately.